Results 281 to 290 of about 4,371,529 (377)
Objective Our objective was to assess the incidence of major adverse cardiovascular events (MACEs) in patients with rheumatoid arthritis (RA) treated with JAK inhibitors (JAKi), tumor necrosis factor inhibitors (TNFi), or biologic disease‐modifying antirheumatic drugs with other modes of action (bDMARD‐OMA) in a multicountry, real‐world population ...
Romain Aymon+28 more
wiley +1 more source
Patent Portfolios Protecting 10 Top-Selling Prescription Drugs.
Horrow C+4 more
europepmc +1 more source
Study on the Prescriptions of Drug Interactions in Hospitalized Patients.
Kiyomi Iwai+3 more
openalex +2 more sources
Estimated Savings From International Reference Pricing for Prescription Drugs.
Mulcahy AW+4 more
europepmc +1 more source
Gout and NLRP3 Inflammasome Biology
This review describes the three broad stages of acute inflammation in the context of gout: initiation, leucocyte mobilization, and self‐resolution. A typical case of a gout flare is presented. The role of the NLRP3 inflammasome in acute monosodium urate crystal–induced inflammation is reviewed in detail.
Raewyn Poulsen, Nicola Dalbeth
wiley +1 more source
On quantitative structure-property relationship (QSPR) analysis of physicochemical properties and anti-hepatitis prescription drugs using a linear regression model. [PDF]
Mahboob A+4 more
europepmc +1 more source
Objectives Tumor necrosis factor inhibitors (TNFi) have significantly improved rheumatoid arthritis (RA) management, yet variability in patient response remains a substantial challenge, with approximately 40% of patients discontinuing TNFi due to non‐response or adverse effects. This study aimed to identify biomarkers predictive of adalimumab treatment
Chuan Fu Yap+12 more
wiley +1 more source
Objectives Dotinurad is a selective urate reabsorption inhibitor that reduces serum urate levels. We compared the efficacy and safety of dotinurad with febuxostat in Chinese patients with gout. Methods This phase 3, multicentre, randomised, double‐blind, parallel‐group study randomly allocated (1:1) eligible patients with gout to receive oral dotinurad
Jia Sun+19 more
wiley +1 more source